Global Home Global Home  
 
 

News

Date Title and Summary Additional Formats
Toggle Summary Sonoma Pharmaceuticals Announces FDA Approval of Expanded Indication for Alevicyn™ to Add Antimicrobial Language
PETALUMA, Calif. , Nov. 16, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced that
View HTML
Toggle Summary Sonoma Pharmaceuticals Reports Robust Top Line Growth for Second Quarter FY 2018 with 61% Product Revenue Growth and Total Revenue of $4.3 Million
Product revenue up 15%, compared to the June 2017 quarter Prescriptions filled were up 42% over last year and up 14% over the June 2017 quarter to 19,660 EBITDA loss reduced to $2.3 million Cash on hand equals $10 million Conference Call Begins at 4:30pm EST Today Slide Presentation to Review in
View HTML
Toggle Summary Sonoma Pharmaceuticals Receives Brazilian Approvals to Market Multiple Hypochlorous Acid-Based Dermatology Products
Brazilian Ministério da Saúde Approves Marketing of Sonoma Pharmaceuticals' Products: Lasercyn™, Gramaderm®, Epicyn™ and Pediacyn™   Brazilian Dermatology Market Second Largest in the World Behind the United States PETALUMA, Calif. , Oct. 31, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc.
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Fiscal Second Quarter 2018 Financial Results and Conference Call
PETALUMA, Calif. , Oct. 26, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced that financial results for its fiscal second quarter 2018, ended September 30, 2017 , will be released after the U.S. markets close on November 9, 2017 .
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces U.S. Commercialization of Loyon® for Relief of Scaling, Burning and Itching Associated with Various Dermatoses Including Seborrhea and Seborrheic Dermatitis
PETALUMA, Calif. , Oct. 03, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced the
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Commercialization of MicrocynAH® Animal Healthcare Products in Japan
PETALUMA, Calif. , Sept. 14, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced the
View HTML
Toggle Summary Sonoma Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018
Product revenue for first quarter up 49%, compared to the same period last year, driven by growth in U.S. dermatology sales Conference Call Begins at 4:30pm EDT Today PETALUMA, Calif. , Aug. 08, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Fiscal First Quarter 2018 Financial Results and Conference Call
PETALUMA, Calif. , July 25, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced that the financial results for its fiscal first quarter 2018, ended June 30, 2017 , will be released after the U.S. markets close on August 8, 2017 .
View HTML
Toggle Summary CORRECTING and REPLACING -- Sonoma Pharmaceuticals Announces Record Quarterly Prescription Data
PETALUMA, Calif. , July 13, 2017 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Sonoma Pharmaceuticals, Inc., please note that in the first paragraph of the release the company ticker symbols should be (NASDAQ:SNOA) (SNOAW), not (NASDAQ:OCLS) (OCLSW) as previously
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Record Quarterly Prescription Data
Highest quarterly prescriptions filled in company's history
View HTML